Steven Cohen Avrobio, Inc. Transaction History

Point72 Asset Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.76 - $1.82 $494,000 - $1.18 Million	650,000 New	650,000 $650,000
Q1 2022 May 16, 2022	SELL	$1.29 - $4.04 $193,500 - $606,000	-150,000 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$3.45 - $6.05 $276,000 - $484,000	-80,000 Reduced 34.78%	150,000 $578,000
Q3 2021 Nov 15, 2021	SELL	$5.53 - $9.28 $1.58 Million - $2.64 Million	-285,000 Reduced 55.34%	230,000 $1.28 Million
Q2 2021 Aug 16, 2021	BUY	$7.84 - $12.6 $892,192 - $1.43 Million	113,800 Added 28.36%	515,000 $4.58 Million
Q1 2021 May 17, 2021	BUY	$10.54 - $19.3 $4.23 Million - $7.74 Million	401,200 New	401,200 $5.09 Million

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.